Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RRDEF
ADC Name
Luveltamab tazevibulin
Synonyms
STRO 002; STRO-002; anti-FolRa ADC STRO-002; DBCO-Alexa647-conjugated SP7219; luvelta
   Click to Show/Hide
Organization
Sutro Biopharma, Inc.; Tasly Biopharmaceuticals Co., Ltd.
Drug Status
Phase 2
Indication
In total 8 Indication(s)
Endometrial cancer [ICD11:2C76]
Phase 2
Fallopian tube cancer [ICD11:2C74]
Phase 2
Ovarian cancer [ICD11:2C73]
Phase 2
Primary peritoneal cancer [ICD11:2C51]
Phase 2
Acute myeloid leukaemia [ICD11:2A60]
Phase 1
Epithelial ovarian cancer [ICD11:2B5D]
Phase 1
Ovary endometrioid adenocarcinoma [ICD11:2C73]
Phase 1
Peritoneal cancer [ICD11:2C51]
Phase 1
Drug-to-Antibody Ratio
4
Antibody Name
Luveltamab
  Antibody Info 
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
SC209
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Val-Cit-PABA
  Linker Info 
Conjugate Type
Site-specific conjugation through unnatural amino acid (pAMF HC-Y180 and HC-F404).
Combination Type
SC239
Special Approval(s)
Fast track(FDA); Orphan drug(FDA)
Puchem SID
461453569 , 472419847 , 476000952 , 472426004 , 474492884
Drugbank ID
DB17563
ChEBI ID
CHEMBL5095133
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
15
%
STRO-002 monotherapy PDX model (PDX:PDX model 5)
Tumor Growth Inhibition value (TGI) 
53
%
PDX model
Tumor Growth Inhibition value (TGI) 
70
%
PDX model
Tumor Growth Inhibition value (TGI) 
80
%
PDX model
Tumor Growth Inhibition value (TGI) 
100
%
PDX model
Tumor Growth Inhibition value (TGI) 
100
%
PDX model
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 26 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.24
nM
NCI-H1703 cells
Lung squamous cell carcinoma
Half Maximal Effective Concentration (EC50) 
0.74
nM
MDA-MB-468 cells
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.84
nM
NCI-H2110 cells
Lung non-small cell carcinoma
Half Maximal Effective Concentration (EC50) 
1.4
nM
A431 cells
Skin squamous cell carcinoma
Half Maximal Effective Concentration (EC50) 
1.42
nM
SK-BR-3 cells
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
1.7
nM
MDA-MB-231 cells
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
1.8
nM
MDA-MB-435 cells
Amelanotic melanoma
Half Maximal Effective Concentration (EC50) 
2.2
nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Half Maximal Effective Concentration (EC50) 
2.29
nM
MDA-MB-435 cells
Amelanotic melanoma
Half Maximal Effective Concentration (EC50) 
2.42
nM
OPM-2 cells
Plasma cell myeloma
Half Maximal Effective Concentration (EC50) 
3.18
nM
HT29 cells
Colon cancer
Half Maximal Effective Concentration (EC50) 
3.59
nM
SK-BR-3 cells
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
7.9
nM
A-549 cells
Lung adenocarcinoma
Half Maximal Effective Concentration (EC50) 
9.18
nM
HCT 116 cells
Colon carcinoma
Half Maximal Effective Concentration (EC50) 
9.2
nM
NCI-H1651 cells
Lung adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.07
ng/mL
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.35
ng/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Half Maximal Effective Concentration (EC50) 
1.42
ng/mL
SU-DHL-6 cells
Diffuse large B-cell lymphoma
Half Maximal Effective Concentration (EC50) 
1.6
ng/mL
Ishikawa cells
Endometrial adenocarcinoma
Half Maximal Effective Concentration (EC50) 
2.1
ng/mL
NCI-N87 cells
Gastric tubular adenocarcinoma
Half Maximal Effective Concentration (EC50) 
2.2
ng/mL
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
Half Maximal Effective Concentration (EC50) 
2.8
ng/mL
OVKATE cells
High grade ovarian serous adenocarcinoma
Half Maximal Effective Concentration (EC50) 
3.6
ng/mL
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
Half Maximal Effective Concentration (EC50) 
3.9
ng/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Half Maximal Effective Concentration (EC50) 
291
ng/mL
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
Half Maximal Effective Concentration (EC50) 
400
ng/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 15.00% Negative FOLR1 expression (FOLR1-)
In Vivo Model STRO-002 monotherapy PDX model (PDX:PDX model 5)
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 53.00% Low FOLR1 expression (FOLR1+)
In Vivo Model PDX model
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 70.00% Moderate FOLR1 expression (FOLR1++)
In Vivo Model PDX model
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 80.00% High FOLR1 expression (FOLR1+++)
In Vivo Model PDX model
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% High FOLR1 expression (FOLR1+++)
In Vivo Model PDX model
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% High FOLR1 expression (FOLR1+++)
In Vivo Model PDX model
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 26 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.24 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Lung squamous cell carcinoma NCI-H1703 cells CVCL_1490
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.74 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.84 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Lung non-small cell carcinoma NCI-H2110 cells CVCL_1530
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.40 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.42 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.70 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.80 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Amelanotic melanoma MDA-MB-435 cells CVCL_0417
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.20 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.29 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Amelanotic melanoma MDA-MB-435 cells CVCL_0417
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.42 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Plasma cell myeloma OPM-2 cells CVCL_1625
Experiment 11 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 3.18 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Colon cancer HT29 cells CVCL_A8EZ
Experiment 12 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 3.59 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 13 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 7.90 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 14 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 9.18 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Colon carcinoma HCT 116 cells CVCL_0291
Experiment 15 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 9.20 nM Low FOLR1 expression (FOLR1+)
In Vitro Model Lung adenocarcinoma NCI-H1651 cells CVCL_1484
Experiment 16 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.07 ng/mL Moderate FOLR1 expression (FOLR1++)
Method Description
STRO-002 in lgrov1 cell.
In Vitro Model Ovarian endometrioid adenocarcinoma IGROV-1 cells CVCL_1304
Experiment 17 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.35 ng/mL High FOLR1 expression (FOLR1+++)
Method Description
STRO-002 in KB cell.
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 18 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.42 ng/mL Low FOLR1 expression (FOLR1+)
In Vitro Model Diffuse large B-cell lymphoma SU-DHL-6 cells CVCL_2206
Experiment 19 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.60 ng/mL Low FOLR1 expression (FOLR1+)
In Vitro Model Endometrial adenocarcinoma Ishikawa cells CVCL_2529
Experiment 20 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.10 ng/mL Low FOLR1 expression (FOLR1+)
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 21 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.20 ng/mL Moderate FOLR1 expression (FOLR1++)
In Vitro Model Ovarian endometrioid adenocarcinoma IGROV-1 cells CVCL_1304
Experiment 22 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.80 ng/mL Low FOLR1 expression (FOLR1+)
In Vitro Model High grade ovarian serous adenocarcinoma OVKATE cells CVCL_3110
Experiment 23 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 3.60 ng/mL Moderate FOLR1 expression (FOLR1++)
Method Description
SC209 in lgrov1 cell.
In Vitro Model Ovarian endometrioid adenocarcinoma IGROV-1 cells CVCL_1304
Experiment 24 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 3.90 ng/mL High FOLR1 expression (FOLR1+++)
Method Description
SC209 in KB cell.
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 25 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 291.00 ng/mL Moderate FOLR1 expression (FOLR1++)
Method Description
SC239 in lgrov1 cell.
In Vitro Model Ovarian endometrioid adenocarcinoma IGROV-1 cells CVCL_1304
Experiment 26 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 400.00 ng/mL High FOLR1 expression (FOLR1+++)
Method Description
SC239 in KB cell.
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
References
Ref 1 Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. Mol Cancer Ther. 2023 Feb 1;22(2):155-167.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.